Pegaspargase is an asparagine-specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for treatment of pediatric and adult patients with first-line acute lymphoblastic leukemia, among other approved uses. MedsAcross supplies Pegaspargase for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ONCASPAR is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for treatment of pediatric and adult patients with: First-line acute lymphoblastic leukemia. Acute lymphoblastic leukemia and hypersensitivity to asparaginase
Source: US FDA prescribing information
L-asparaginase is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. The pharmacological effect of ONCASPAR is thought to be based on the killing of leukemic cells due to depletion of plasma asparagine. Leukemic cells with low expression of asparagine synthetase have a reduced ability to synthesize asparagine, and therefore depend on an exogenous source of asparagine for survival.
Source: US FDA prescribing information
Administered intramuscularly or intravenously no more frequently than every 14 days. Patients ages 21 years and younger: 2,500 International Units/m 2. Patients ages over 21 years: 2,000 International Units/m 2. For intramuscular administration, limit the volume at a single injection site to 2 mL, if greater than 2 mL, use multiple injection sites. For intravenous administration, give over a period of 1 to 2 hours in 100 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP through an infusion that is already running. Do not administer ONCASPAR if drug has been frozen, stored at room temperature for more than 48 hours, or shaken or vigorously agitated.
Source: US FDA prescribing information
ONCASPAR is contraindicated in patients with a: History of serious hypersensitivity reactions, including anaphylaxis, to ONCASPAR or to any of the excipients. History of serious thrombosis with prior L-asparaginase therapy. History of pancreatitis, including pancreatitis related to prior L-asparaginase therapy. History of serious hemorrhagic events with prior L-asparaginase therapy. Severe hepatic impairment. History of serious hypersensitivity reactions to ONCASPAR. History of pancreatitis with prior L-asparaginase therapy.
Source: US FDA prescribing information
Anaphylaxis or serious hypersensitivity reactions: Observe patients for 1 hour after administration. Discontinue ONCASPAR in patients with serious hypersensitivity reactions. Thrombosis: Discontinue ONCASPAR in patients with serious thrombotic events. Pancreatitis: Evaluate patients with abdominal pain for pancreatitis. Discontinue ONCASPAR in patients with pancreatitis. Glucose intolerance: Monitor serum glucose. Hemorrhage: Discontinue ONCASPAR for severe or life-threatening hemorrhage. Evaluate for etiology and treat. Hepatotoxicity, including hepatic veno-occlusive disease (VOD): Monitor for toxicity through recovery from cycle. Discontinue ONCASPAR for severe liver toxicity.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Anaphylaxis and serious hypersensitivity reactions Thrombosis Pancreatitis Glucose intolerance Hemorrhage Hepatotoxicity, including VOD The most common (>5%) grade > 3 adverse reactions with ONCASPAR are hypoalbuminemia, elevated transaminase, febrile neutropenia, hypertriglyceridemia, hyperglycemia, bilirubin increased, pancreatitis, abnormal clotting studies, embolic and thrombotic events, hypersensitivity, sepsis, and infections.
Source: US FDA prescribing information
Glucocorticoids Pegaspargase may increase the risk of glucocorticoid-induced toxicities, including osteonecrosis through a potential increase in exposure of dexamethasone.
Source: US FDA prescribing information
Store ONCASPAR refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not shake or freeze product. Unopened vials may be stored at room temperature (15°C to 25°C [59°F to 77°F]) for no more than 48 hours.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Pegaspargase, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Oncaspar 750 IU/mL injectionIntramuscular, intravenous Cold chain | Servier Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Pegaspargase in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Pegaspargase and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Pegaspargase, including Oncaspar.
Yes. The US FDA first approved Pegaspargase on 1 February 1994, according to Drugs@FDA.
Yes. Pegaspargase has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Pegaspargase must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Pegaspargase is classified under ATC code L01XX24 (Pegaspargase).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.